Shots:
- The EC has approved Dawnzera (SC autoinjector; Q4W/Q8W) for the routine prevention of HAE attacks in pts (≥12yrs.)
- Approval was based on P-III (OASIS-HAE) trial & OASISplus study, showing improvements across multiple domains, incl. sustained reduction in mean monthly HAE attack rate, with 94% overall mean monthly reduction at 1yr. in the OASISplus OLE study
- Approval triggered $15M milestone payment to Ionis, along with tiered royalties of up to 30% on product sales under its deal with Otsuka, which granted Otsuka exclusive rights to Dawnzera across EU & APAC
Ref: Businesswire | Image: Ionis and Otsuka | Press Release
Related News:
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
